Notwithstanding promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable difficulty from PBMs. These companies are frequently https://rafaelwqfs206387.mpeblog.com/76249439/company-s-drug-faces-is-encountering-pbm-hurdles-the-review-at-reimbursement-fights